Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
Zynyz Receives FDA Accelerated Approval for Merkel-Cell Carcinoma
FDA Approvals, News & Updates
,
Skin Cancer
April 2023, Vol 14, No 2
On
March 22, 2023
, the FDA granted accelerated approval to retifanlimab-dlwr (Zynyz; Incyte Corporation), a programmed cell death 1–blocking antibody, for the treatment of adult patients with metastatic or recurrent locally advanced Merkel-cell carcinoma.
Read More
Tafinlar plus Mekinist Combination Approved for Pediatric Low-Grade Glioma with BRAFᵛ⁶⁰⁰ᴱ Mutation
FDA Approvals, News & Updates
,
Head and Neck Cancer
April 2023, Vol 14, No 2
On
March 16, 2023
, the FDA approved dabrafenib (Tafinlar; Novartis) in combination with trametinib (Mekinist; Novartis) for the treatment of pediatric patients aged ≥1 year with low-grade glioma that harbors a
BRAF
V600E
mutation and who require systemic therapy.
Read More
FDA Expands Indication for Verzenio as Adjuvant Treatment for HR-Positive, HER2-Negative, Early Breast Cancer
FDA Approvals, News & Updates
,
Breast Cancer
April 2023, Vol 14, No 2
On
March 3, 2023
, the FDA approved abemaciclib (Verzenio; Eli Lilly) plus endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive,
HER2
-negative, node-positive, early breast cancer at high risk for recurrence.
Read More
Jemperli Receives Regular FDA Approval for Advanced Endometrial Cancer
FDA Approvals, News & Updates
,
Gynecologic Cancer
,
Endometrial Cancer
April 2023, Vol 14, No 2
On
February 9, 2023
, the FDA approved dostarlimab-gxly (Jemperli; GlaxoSmithKline) for the treatment of adult patients with mismatch repair-deficient, recurrent or advanced endometrial cancer, as determined by an FDA-approved test, whose disease has progressed on or following a previous platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
Read More
Trodelvy Now Approved for Pretreated Patients with HR-Positive, HER2-Negative Breast Cancer
FDA Approvals, News & Updates
,
Breast Cancer
April 2023, Vol 14, No 2
On
February 3, 2023
, the FDA approved sacituzumab govitecan-hziy (Trodelvy; Gilead Sciences/Immunomedics) for the treatment of patients with unresectable, locally advanced or metastatic hormone receptor (HR)-positive,
HER2
-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+ with a negative in situ hybridization test) breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting.
Read More
Pausing Endocrine Therapy to Become Pregnant Appears Safe for Women with Breast Cancer
By
Phoebe Starr
Women's Health
,
Breast Cancer
April 2023, Vol 14, No 2
Young women with early-stage, hormone receptor-positive breast cancer attempting to become pregnant can safely pause endocrine therapy and resume it later, according to initial results from the international POSITIVE trial.
Read More
Addressing Health Equity in Bladder Cancer Care
By
Wayne Kuznar
ASCO GU 2023 HIGHLIGHTS
,
Bladder Cancer
,
Genitourinary Cancers
April 2023, Vol 14, No 2
During the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, a panel of experts identified some of the key challenges to achieving health equity in bladder cancer care and discussed what can be done to improve access to clinical trials, mitigate financial toxicity, and promote value-based care.
Read More
ACS Reports Shift in Colorectal Cancer to Advanced Stage and Younger Age at Diagnosis
By
Anne Rowe
Colorectal Cancer
April 2023, Vol 14, No 2
A new report released by the American Cancer Society (ACS) shows that the incidence of colorectal cancer is rapidly increasing among younger individuals, and the disease is also being diagnosed at more advanced stages in people of all ages.
Read More
What Will It Take to End Cancer As We Know It?
By
Wayne Kuznar
ASCO GU 2023 HIGHLIGHTS
April 2023, Vol 14, No 2
In his keynote address at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, Norman E. “Ned” Sharpless, MD, Former Director of the National Cancer Institute, and Professor, Cancer Policy and Innovation, University of North Carolina School of Medicine, Chapel Hill, told attendees that although cancer-related mortality is declining, challenges remain to “end cancer as we know it.”
Read More
Choosing Adjuvant Treatment for Patients with RCC Requires Careful Consideration of Risks and Benefits
By
Wayne Kuznar
ASCO GU 2023 HIGHLIGHTS
,
Renal-Cell Carcinoma
,
Genitourinary Cancers
April 2023, Vol 14, No 2
The decision to use adjuvant therapies in patients with renal-cell carcinoma (RCC) should be based on risk, patient goals, and shared decision-making. This topic was explored in a presentation by Matthew Zibelman, MD, Associate Professor, Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Read More
Page 8 of 338
3
4
5
6
7
8
9
10
11
12
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma